Prelude Therapeutics (PRLD) Competitors $1.21 +0.07 (+6.23%) As of 02:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. CTNM, VOR, DBVT, MREO, JBIO, LXEO, PBYI, ALLO, TVRD, and GALTShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Contineum Therapeutics (CTNM), Vor Biopharma (VOR), DBV Technologies (DBVT), Mereo BioPharma Group (MREO), Jade Biosciences (JBIO), Lexeo Therapeutics (LXEO), Puma Biotechnology (PBYI), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Its Competitors Contineum Therapeutics Vor Biopharma DBV Technologies Mereo BioPharma Group Jade Biosciences Lexeo Therapeutics Puma Biotechnology Allogene Therapeutics Tvardi Therapeutics Galectin Therapeutics Prelude Therapeutics (NASDAQ:PRLD) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership. Do insiders and institutionals have more ownership in PRLD or CTNM? 79.7% of Prelude Therapeutics shares are owned by institutional investors. 63.9% of Prelude Therapeutics shares are owned by insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is PRLD or CTNM more profitable? Contineum Therapeutics' return on equity of -29.75% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -106.50% -79.07% Contineum Therapeutics N/A -29.75%-28.08% Which has more volatility and risk, PRLD or CTNM? Prelude Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Does the media favor PRLD or CTNM? In the previous week, Contineum Therapeutics had 3 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Contineum Therapeutics and 0 mentions for Prelude Therapeutics. Contineum Therapeutics' average media sentiment score of 0.70 beat Prelude Therapeutics' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Prelude Therapeutics Neutral Contineum Therapeutics Positive Which has higher earnings & valuation, PRLD or CTNM? Contineum Therapeutics has higher revenue and earnings than Prelude Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M9.79-$127.17M-$1.64-0.74Contineum Therapeutics$50M6.46-$42.26M-$2.20-5.24 Do analysts prefer PRLD or CTNM? Prelude Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 230.31%. Contineum Therapeutics has a consensus target price of $22.75, suggesting a potential upside of 97.48%. Given Prelude Therapeutics' higher possible upside, equities analysts plainly believe Prelude Therapeutics is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryContineum Therapeutics beats Prelude Therapeutics on 9 of the 16 factors compared between the two stocks. Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.64M$2.63B$5.77B$9.91BDividend YieldN/A49.35%6.67%4.51%P/E Ratio-0.7323.2975.8026.59Price / Sales9.79733.92555.58120.92Price / CashN/A169.7737.1158.92Price / Book0.515.4311.446.06Net Income-$127.17M$32.95M$3.29B$266.42M7 Day Performance0.08%1.71%0.41%-0.17%1 Month Performance43.94%6.72%6.69%3.69%1 Year Performance-74.82%0.13%59.20%23.46% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics3.6496 of 5 stars$1.21+6.2%$4.00+230.3%-78.0%$67.64M$7M-0.73120CTNMContineum Therapeutics2.7055 of 5 stars$10.39+4.5%$22.75+119.0%-37.8%$278.74M$50M0.0031News CoverageShort Interest ↑VORVor Biopharma0.5418 of 5 stars$2.06-5.1%N/AN/A$274.90MN/A0.00140Gap UpDBVTDBV Technologies3.1893 of 5 stars$9.79-2.1%$14.75+50.7%+124.7%$273.90M$4.15M-2.0580Gap DownMREOMereo BioPharma Group2.5032 of 5 stars$1.74+2.4%$7.40+325.3%-60.2%$270.30M$10M0.0040JBIOJade Biosciences2.7142 of 5 stars$7.90-4.0%$16.00+102.5%N/A$268.52MN/A0.0020LXEOLexeo Therapeutics2.1288 of 5 stars$4.66-4.9%$15.33+229.0%-55.6%$264.61M$650K0.0058Positive NewsPBYIPuma Biotechnology4.3203 of 5 stars$4.99-5.0%$7.00+40.3%+116.5%$264.45M$230.50M5.09200ALLOAllogene Therapeutics2.4187 of 5 stars$1.16-2.5%$8.44+628.0%-57.0%$264.04M$20K-1.05310Analyst RevisionTVRDTvardi TherapeuticsN/A$29.20+4.1%$64.25+120.0%N/A$263.04M$7.14M0.0080Positive NewsGap UpGALTGalectin Therapeutics1.9226 of 5 stars$4.00-2.4%$6.00+50.0%+90.6%$262.65MN/A-6.259 Related Companies and Tools Related Companies Contineum Therapeutics Alternatives Vor Biopharma Alternatives DBV Technologies Alternatives Mereo BioPharma Group Alternatives Jade Biosciences Alternatives Lexeo Therapeutics Alternatives Puma Biotechnology Alternatives Allogene Therapeutics Alternatives Tvardi Therapeutics Alternatives Galectin Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRLD Stock Alerts